Nothing Special   »   [go: up one dir, main page]
create a website
The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine. (2006). Attridge, Jim ; Sheridan, Desmond.
In: PharmacoEconomics.
RePEc:spr:pharme:v:24:y:2006:i:2:p:35-54.

Full description at Econpapers || Download paper

Cited: 2

Citations received by this document

Cites: 61

References cited by this document

Cocites: 43

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

  1. Il prezzo di riferimento nel quadro regolatorio del mercato farmaceutico. (2007). SALERNO, Nicola ; Riccaboni, Massimo ; Pammolli, Fabio ; Magazzini, Laura ; Bonassi, Chiara.
    In: Working Papers CERM.
    RePEc:ern:wpaper:04-2007.

    Full description at Econpapers || Download paper

  2. Regolazione, innovazione e ciclo di vita dei prodotti - per una riforma del pricing al lancio e della governance della spesa nella farmaceutica pubblica. (2007). SALERNO, Nicola ; Riccaboni, Massimo ; Pammolli, Fabio ; Bonassi, Chiara.
    In: Working Papers CERM.
    RePEc:ern:wpaper:02-2007.

    Full description at Econpapers || Download paper

References

References cited by this document

  1. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978; 40(10): 1069–118.
    Paper not yet in RePEc: Add citation now
  2. Abel-Smith B, Mossialos E. Cost containment and healthcare reform: a study of the European Union, Health Policy 1994; 28: 89.
    Paper not yet in RePEc: Add citation now

  3. Achilladelis B, Antonakis N. The dynamics of technological innovation: the case of the pharmaceutical industry. Res Policy 2001; 30: 535–538.

  4. Ahlquist RP. A study of adrenotropic receptors. Am J Physiol 1948; 153: 586–600.
    Paper not yet in RePEc: Add citation now
  5. Allegemeine Ortskrankenkassen Annual Statistics; 1990–2000. Berlin: Germany.
    Paper not yet in RePEc: Add citation now
  6. Black JW, Duncan WA, Shanks RG. Comparison of some properties of pronethalol and propranolol. Br J Pharmacol Chemother 1965; 25: 577–91.
    Paper not yet in RePEc: Add citation now
  7. Brown MS, Goldstein JL. Receptor mediated control of cholesterol metabolism. Science 1976; 191: 150–4.
    Paper not yet in RePEc: Add citation now
  8. Byon KY, Fleckenstein A. Parallel influence of isometric tension development and O2 consumption of isolated papillary muscles under the influence of Ca ions, adrenaline, isoproteranol and organic Ca antagonists (iproveratril, D 600, prenylamine). Pflugers Arch 1969; 312(1): R8–9.
    Paper not yet in RePEc: Add citation now
  9. CIBIS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) a randomised trial. Lancet 1999; 353: 9–13.
    Paper not yet in RePEc: Add citation now
  10. Clausen J. Financing of prescription drugs in Denmark. Presented to The Third European Conference on Health Economics; 20–22 August, 1995, Stockholm, Sweden.
    Paper not yet in RePEc: Add citation now
  11. Colhoun HM, Betteridge DJ, Durrington PN, et al., on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS); multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96.
    Paper not yet in RePEc: Add citation now
  12. Comroe JH. Retrospectoscope: insights into medical discovery. Menlo Park (CA): Von Gehr Press, 1977.
    Paper not yet in RePEc: Add citation now
  13. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35.
    Paper not yet in RePEc: Add citation now

  14. Danzon PM, Kim JD. The life cycle of pharmaceuticals: a cross-national perspective. London: Office of Health Economics monograph, 2002.

  15. Danzon PM. Reference pricing: theory and evidence. In: Lopez-Casasnovas G, Jonsson B, editors. Reference pricing and pharmaceutical policy — perspectives on economics and innovation series. Barcelona: Springer Verlag Iberica, 2001: 86–126.
    Paper not yet in RePEc: Add citation now
  16. Dickson M, Redwood H. Pharmaceutical reference prices: how do they work in practice? Pharmacoeconomics 1998; 14(5): 471–9.
    Paper not yet in RePEc: Add citation now

  17. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22(2): 151–85.

  18. DiMasi JA, Paquette L. The economics of follow on drug R&D — trends in entry rates and timing of development. Pharmacoeconomics 2004; 22 Suppl. 2: 1–14.
    Paper not yet in RePEc: Add citation now
  19. Ekelund M. Generic entry before and after reference prices. Stockholm: Stockholm School of Economics, working paper mimeo, 2000.
    Paper not yet in RePEc: Add citation now
  20. Fagerberg J, Mowery C, Nelson RR, editors. The Oxford handbook of innovation. Oxford: Oxford University Press, 2004.
    Paper not yet in RePEc: Add citation now
  21. Fattore G. Cost containment and reforms in the Italian NHS. In: Mossialos E, LeGrand J, editors. Health care and cost containment in the EU. Aldershot (UK): Ashgate, 1999: 102–122. See also Italian Ministry of Health Department for the Protection of Human Health, Directorate for the Evaluation of Medical Product and Pharmacovigilance, Decree Law ‘Reclassification of Medicinal Products pursuant to article 9, subsection 2 and 3 of law of 8th August 2002, No 178’. Rome, Italy.
    Paper not yet in RePEc: Add citation now
  22. Frank RG, Salkever DS. Generic entry and the price of pharmaceuticals. J Econ Manag Strat 1997; 6: 75–79.
    Paper not yet in RePEc: Add citation now
  23. Freemantle N, Hill S. Evaluating pharmaceuticals for health policy and reimbursement. Oxford: BMJ Books/Blackwell, 2004.
    Paper not yet in RePEc: Add citation now
  24. Gelijns AC. Capturing the unexpected benefits of medical research. N Engl J Med 1998; 339(10): 693–8.
    Paper not yet in RePEc: Add citation now

  25. Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy 1998; 46: 73–85.

  26. Grabowski HG, Vernon JM. A new look at the returns and risks to pharmaceutical R&D. Manag Sci 1990; 36(7): 804–809.

  27. Grabowski HG, Vernon JM. Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act. J Law Econ 1992; 35: 331–335.

  28. Grabowski HG, Vernon JM. Longer patents for increased generic competition in the US: the Waxman-Hatch Act after one decade. Pharmacoeconomics 1996; 10 Suppl. 2: 110–23.
    Paper not yet in RePEc: Add citation now
  29. Grabowski HG. Are the economics of pharmaceutical R&D changing? Pharmacoeconomics 2004; 22 Suppl. 2: 15–24.
    Paper not yet in RePEc: Add citation now
  30. Grubert N. The impact of reference pricing in Europe. Waltham (MA): Spectrum, Decision Resources, 2005.
    Paper not yet in RePEc: Add citation now
  31. Haussler B, Gothe H, Reschke P, et al. ‘Me too’ drugs on the market: occurrence, value and impact on health insurers, Working paper. Berlin: Institut fur Gesundheits und Sozialforschung, 2004. Also available at: lesgaliesg.de [Accessed 10 December 2005].
    Paper not yet in RePEc: Add citation now
  32. Head A, Kendall MJ, Maxwell S. Exercise metabolism during one hour of treadmill walking, while taking high and low doses of propranolol, metoprolol or placebo. Clin Cardiol 1995: 18: 335–40.
    Paper not yet in RePEc: Add citation now
  33. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals: a randomised placebo controlled trial. Lancet 2002; 306: 7–22.
    Paper not yet in RePEc: Add citation now
  34. Institut fur Qualitat und Wirtschaftlichkeitswesen [online]. Available from URL: http://www.IQWiG.de [Accessed 3 December 2005].
    Paper not yet in RePEc: Add citation now
  35. Jonnson B. Reference pricing: central economic and policy issues. In: Lopez-Casasnovas G, Jonsson B, editors. Reference pricing and pharmaceutical policy — perspectives on economics and innovation series. Barcelona: Springer Verlag Iberica, 2001: 80–5.
    Paper not yet in RePEc: Add citation now
  36. Jonsson B, Ekelund M. Reference pricing and innovation in medicine. In: Lopez-Casasnovas G, Jonsson B, editors. Reference pricing and pharmaceutical policy — perspectives on economics and innovation series. Barcelona: Springer Verlag Iberica, 2001: 63–79.
    Paper not yet in RePEc: Add citation now
  37. Joshi PI, Dalal JJ, Ruttley MS, et al. Nifedipine and left ventricular function in beta-blocked patients, Br Heart J 1981;,45(4): 457–9.
    Paper not yet in RePEc: Add citation now
  38. Kang PM, Landou AJ, Eberhardt RT, et al. Angiotensin II receptor antagonists: a new approach to blockade of the reninangiotensin system. Am Heart J 1994; 127: 1388–401.
    Paper not yet in RePEc: Add citation now
  39. Landau R, Achilladelis B, Scriabine A. Pharmaceutical innovation. Philadelphia (PA): Chemical Heritage Foundation, 1999.
    Paper not yet in RePEc: Add citation now
  40. Lands AM, Arnold A, McAuliff JA, et al. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967; 214: 597–8.
    Paper not yet in RePEc: Add citation now
  41. London School of Economics. EU, WHO Observatory; worldwide survey on pharmaceutical price and reimbursement systems [online]. Available from URL: http://pharmacos.eudra.org [Accessed 15 October 2005].
    Paper not yet in RePEc: Add citation now
  42. Long J. IMS presentation to World Wholesalers Association conference, Shanghai, China, 22–24 September 2004.
    Paper not yet in RePEc: Add citation now
  43. Lopez-Casasnovas G, Jonsson B, editors. Reference pricing and pharmaceutical policy — perspectives on economics and innovation series, Barcelona: Springer Verlag Iberica, 2001.
    Paper not yet in RePEc: Add citation now
  44. Lopez-Casasnovas G, Puig-Junoy J. In: Lopez-Casasnovas G, Jonsson B, editors. Chapter 1: Reference pricing and pharmaceutical policy — perspectives on economics and innovation series. Barcelona: Springer Verlag Iberica, 2001: 1–41.
    Paper not yet in RePEc: Add citation now
  45. Mark AL. Sympathetic dysregulation in heart failure; mechanisms and therapy. Clin Cardiol 1995; 18 Suppl. I: I–3–I–8.
    Paper not yet in RePEc: Add citation now
  46. McArthur WJ. Patient outcomes and public health consequences of reference pricing. In: Lopez-Casasnovas G, Jonsson B, editors. Reference pricing and pharmaceutical policy — perspectives on economics and innovation series, Barcelona: Springer Verlag Iberica, 2001: 145–60.
    Paper not yet in RePEc: Add citation now
  47. Mrazek M, Mossialos E. Increasing demand while decreasing costs of generic medicines. Lancet 2000; 356: 1784–5.
    Paper not yet in RePEc: Add citation now
  48. Pharma pipelines. Lehman Brothers, Global Equity Research-Pharmaceuticals, 2003, London: United Kingdom.
    Paper not yet in RePEc: Add citation now
  49. Ringer S. Concerning the action of calcium, potassium, and sodium salts upon the eel’s heart and upon the skeletal muscles of the frog. J Physiol 1887; 8: 15–9.
    Paper not yet in RePEc: Add citation now
  50. Rinkenberger RL, Prystowsky EN, Heger JJ, et al. Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation 1980; 62: 996–1010.
    Paper not yet in RePEc: Add citation now
  51. Rolf-Smith S, Kendall MJ, Worthington DJ, et al. Can the biochemical responses to a beta 2-adrenoceptor stimulant be used to assess selectivity of beta-adrenoceptor blockers? Br J Clin Pharmacol 1983; 16: 557–60.
    Paper not yet in RePEc: Add citation now
  52. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
    Paper not yet in RePEc: Add citation now
  53. Selke G. Reference price systems in the European Community. In: Mossialos E, Ranos C, Abel-Smith B, editors. Cost containment: pricing and financing of pharmaceuticals in the European Community: the policy makers view. Athens: LSE Health and Pharmetrica SA, 1994: 147–60.
    Paper not yet in RePEc: Add citation now
  54. Sever PS, Dahlof B, Poulter NR, et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes trial — Lipid lowering arm (ASCOT-LLA); a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
    Paper not yet in RePEc: Add citation now
  55. Survey of patient co-payment levels by national pharma industry associations. Brussels: EFPIA Report, 2001.
    Paper not yet in RePEc: Add citation now
  56. Svedmyr N. Fentorol: a beta 2-adrenergic agonist for use in asthma; pharmacology, pharmokinetics, clinical efficacy and adverse effects. Pharmacotherapy 1985; 5: 109–26.
    Paper not yet in RePEc: Add citation now
  57. Sweeney K. Australian pharmaceutical pricing in a global context, Working paper 19, Centre for Strategic Economic Studies, Victoria University of Technology, Melbourne, Australia 2004 [online]. Available from URL: http://www.cfses.com [Accessed 21 November 2005].
    Paper not yet in RePEc: Add citation now
  58. Vos CM. The 1996 price and reimbursement policy in the Netherlands. Pharmacoeconomics 1996; 10 Suppl. 2 75–80.
    Paper not yet in RePEc: Add citation now

  59. Wells N. Innovative chemical extensions — the economic basis of pharmaceutical progress. London: Office of Health Economics monograph, 1988.

  60. Woodfield AE. Reference pricing: theory and evidence from New Zealand. In: Lopez-Casasnovas G, Jonsson B, editors. Reference pricing and pharmaceutical policy — perspectives on economics and innovation series. Barcelona: Springer Verlag Iberica, 2001: 127–44.
    Paper not yet in RePEc: Add citation now
  61. Yusef S, Sleight P, Pogue J, et al. Effects of an angiotensin converting enzyme inhibitor, ramipril on cardiovascular events in high risk patients: the Heart Outcomes Prevention Evaluation Study Investigation. N Engl J Med 2000; 342: 145–53.
    Paper not yet in RePEc: Add citation now

Cocites

Documents in RePEc which have cited the same bibliography

  1. When is industry ‘sustainable’? The economics of institutional variety in a pandemic. (2023). Srinivas, Smita.
    In: Review of Evolutionary Political Economy.
    RePEc:spr:revepe:v:4:y:2023:i:1:d:10.1007_s43253-023-00093-y.

    Full description at Econpapers || Download paper

  2. Determinants of radical drug innovation: a systematic literature review. (2022). Cambre, Bart ; Witteloostuijn, Arjen ; Stiller, Ingo.
    In: Management Review Quarterly.
    RePEc:spr:manrev:v:72:y:2022:i:4:d:10.1007_s11301-021-00218-9.

    Full description at Econpapers || Download paper

  3. Morphological Change and Internal Growth Factors of Firms in the Korean Pharmaceutical Industry in Recent Decades. (2022). Lee, Heesang ; Kim, Jinju ; Ha, Taejin ; In, Seung.
    In: Sustainability.
    RePEc:gam:jsusta:v:14:y:2022:i:22:p:15339-:d:976952.

    Full description at Econpapers || Download paper

  4. .

    Full description at Econpapers || Download paper

  5. Do current radical innovation measures actually measure radical drug innovation?. (2021). Witteloostuijn, Arjen ; Stiller, Ingo ; Cambre, Bart.
    In: Scientometrics.
    RePEc:spr:scient:v:126:y:2021:i:2:d:10.1007_s11192-020-03778-x.

    Full description at Econpapers || Download paper

  6. .

    Full description at Econpapers || Download paper

  7. .

    Full description at Econpapers || Download paper

  8. Innovation in pharmaceutical R&D: mapping the research landscape. (2020). Sijde, Peter ; Kenneth, Angelo ; Muijlwijk-Koezen, Jacqueline.
    In: Scientometrics.
    RePEc:spr:scient:v:125:y:2020:i:3:d:10.1007_s11192-020-03707-y.

    Full description at Econpapers || Download paper

  9. Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies. (2020). Lim, Yeongjoo ; Makino, Tomohiro ; Teramae, Fumio ; Kodama, Kota ; Sengoku, Shintaro.
    In: Sustainability.
    RePEc:gam:jsusta:v:12:y:2020:i:13:p:5358-:d:379480.

    Full description at Econpapers || Download paper

  10. RELATIONSHIP BETWEEN TECHNOLOGICAL ECO-INNOVATION CAPACITY AND INNOVATION PERFORMANCE: EVIDENCE FROM MOST INNOVATIVE FIRMS IN THE USA. (2019). Martins, Selma Regina .
    In: Proceedings of the INTERNATIONAL MANAGEMENT CONFERENCE.
    RePEc:rom:mancon:v:13:y:2019:i:1:p:163-178.

    Full description at Econpapers || Download paper

  11. From Basic Research to Competitiveness: An Econometric Analysis of the Global Pharmaceutical Sector. (2019). Máté, Domicián ; Kiss, Anna ; Lakner, Zoltan ; Olah, Judit ; Mate, Domician ; Zeman, Zoltan ; Popp, Jozsef.
    In: Sustainability.
    RePEc:gam:jsusta:v:11:y:2019:i:11:p:3125-:d:236763.

    Full description at Econpapers || Download paper

  12. Effects of standardization on the evolution of information and communications technology. (2018). Lee, Won Sang ; Young, SO.
    In: Technological Forecasting and Social Change.
    RePEc:eee:tefoso:v:132:y:2018:i:c:p:308-317.

    Full description at Econpapers || Download paper

  13. University–Industry collaboration in the biopharmaceuticals: the Italian case. (2016). Pericoli, Filippo Maria ; Giunta, Anna ; Pierucci, Eleonora.
    In: The Journal of Technology Transfer.
    RePEc:kap:jtecht:v:41:y:2016:i:4:d:10.1007_s10961-015-9402-2.

    Full description at Econpapers || Download paper

  14. The parents legacy: Firm founders and technological choice. (2016). Howard, Michael D ; Boeker, Warren ; Basu, Sandip ; Sahaym, Arvin.
    In: Journal of Business Research.
    RePEc:eee:jbrese:v:69:y:2016:i:8:p:2624-2633.

    Full description at Econpapers || Download paper

  15. Salesforce management factors for successful new product launch. (2016). Fraenkel, Stefan ; Haftor, Darek M ; Pashkevich, Natallia .
    In: Journal of Business Research.
    RePEc:eee:jbrese:v:69:y:2016:i:11:p:5053-5058.

    Full description at Econpapers || Download paper

  16. Industrial policy and employment in the UK: evidence from the pharmaceutical sector. (2016). Hannon, Enda .
    In: Industrial Relations Journal.
    RePEc:bla:indrel:v:47:y:2016:i:1:p:2-20.

    Full description at Econpapers || Download paper

  17. Modelling to assess the impact of technological innovation capacity in the performance of high complexity environments. (2015). Martins, Selma Regina ; Sbragia, Roberto.
    In: International Journal of Business Performance and Supply Chain Modelling.
    RePEc:ids:ijbpsc:v:7:y:2015:i:1:p:12-35.

    Full description at Econpapers || Download paper

  18. Divergence and convergence of commercial and scientific priorities in drug development: The case of Zelmid, the first SSRI antidepressant. (2015). Mulinari, Shai .
    In: Social Science & Medicine.
    RePEc:eee:socmed:v:138:y:2015:i:c:p:217-224.

    Full description at Econpapers || Download paper

  19. Evolution of Capabilities in the Discovery Cycle of an Innovation in the Pharmaceutical Market. (2015). Veiga, Claudimar Pereirada ; del Corso, Jansen Maia ; Kato, Heitor Takashi ; Giacomini, Monica Maier ; CaSSIA RITA PEREIRA DA VEIGA, .
    In: International Review of Management and Marketing.
    RePEc:eco:journ3:2015-03-06.

    Full description at Econpapers || Download paper

  20. Capital outflow and R&D investment in the parent firm. (2013). Huang, Shu-Chin .
    In: Research Policy.
    RePEc:eee:respol:v:42:y:2013:i:1:p:245-260.

    Full description at Econpapers || Download paper

  21. Catching up in the Pharmaceutical Sector: Lessons from Case Studies of India and Brazil. (2012). Guennif, Samira ; Ramani, Shyama V..
    In: Chapters.
    RePEc:elg:eechap:14616_5.

    Full description at Econpapers || Download paper

  22. Input substitutability, trade costs and location. (2012). Michalski, Tomasz.
    In: Economics Letters.
    RePEc:eee:ecolet:v:117:y:2012:i:1:p:57-59.

    Full description at Econpapers || Download paper

  23. Catching up in pharmaceuticals: a comparative study of India and Brazil. (2010). Ramani, Shyama ; guennif, samira.
    In: MERIT Working Papers.
    RePEc:unm:unumer:2010019.

    Full description at Econpapers || Download paper

  24. Catching up in pharmaceuticals: a comparative study of India and Brazil. (2010). Guennif, Samira ; Ramani, Shyama .
    In: Working Papers.
    RePEc:hal:wpaper:hal-00632439.

    Full description at Econpapers || Download paper

  25. Catching up in pharmaceuticals: a comparative study of India and Brazil. (2010). Ramani, Shyama ; guennif, samira.
    In: CEPN Working Papers.
    RePEc:hal:cepnwp:hal-00632439.

    Full description at Econpapers || Download paper

  26. Building National and Regional Innovation Systems. (2010). Niosi, Jorge.
    In: Books.
    RePEc:elg:eebook:14006.

    Full description at Econpapers || Download paper

  27. Knowledge sources, patent protection, and commercialization of pharmaceutical innovations. (2010). Sternitzke, Christian.
    In: Research Policy.
    RePEc:eee:respol:v:39:y:2010:i:6:p:810-821.

    Full description at Econpapers || Download paper

  28. Evaluation of policies to support drug development in New Zealand. (2010). Lockhart, Michelle ; Babar, Zaheer Ud-Din ; Garg, Sanjay .
    In: Health Policy.
    RePEc:eee:hepoli:v:96:y:2010:i:2:p:108-117.

    Full description at Econpapers || Download paper

  29. Attentional Triangulation: Learning from Unexpected Rare Crises. (2009). Rerup, Claus .
    In: Organization Science.
    RePEc:inm:ororsc:v:20:y:2009:i:5:p:876-893.

    Full description at Econpapers || Download paper

  30. OUTSOURCING OF RESEARCH AND DEVELOPMENT ACTIVITIES: EVIDENCE FROM U.S. BIOPHARMACEUTICAL FIRMS. (2009). Sen, Arup K..
    In: Global Journal of Business Research.
    RePEc:ibf:gjbres:v:3:y:2009:i:1:p:73-82.

    Full description at Econpapers || Download paper

  31. A national systems view of university entrepreneurialism: Inferences from comparison of the German and US experience. (2009). Garber, Lisa ; Nell, Phillip ; Lehrer, Mark .
    In: Research Policy.
    RePEc:eee:respol:v:38:y:2009:i:2:p:268-280.

    Full description at Econpapers || Download paper

  32. Facing the Trial of Internationalizing Clinical Trials to Developing Countries: Some Evidence from Mexico. (2008). Santiago, Fernando ; Santiago-Rodriguez, Fernando .
    In: MERIT Working Papers.
    RePEc:unm:unumer:2008023.

    Full description at Econpapers || Download paper

  33. Strategic procurement, openness and market structure. (2008). Levine, Paul ; Garcia-Alonso, Maria ; García-Alonso, María D. C., .
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:26:y:2008:i:5:p:1180-1190.

    Full description at Econpapers || Download paper

  34. Product innovation and process innovation in SOEs: evidence from the Chinese transition. (2007). Li, Yuan ; Liu, YI ; Ren, Feng.
    In: The Journal of Technology Transfer.
    RePEc:kap:jtecht:v:32:y:2007:i:1:p:63-85.

    Full description at Econpapers || Download paper

  35. The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine. (2006). Attridge, Jim ; Sheridan, Desmond.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:24:y:2006:i:2:p:35-54.

    Full description at Econpapers || Download paper

  36. Industrial Development and Innovation: Some Lessons from Vaccine Procurement. (2006). Srinivas, Smita.
    In: World Development.
    RePEc:eee:wdevel:v:34:y:2006:i:10:p:1742-1764.

    Full description at Econpapers || Download paper

  37. Marketing/R&D integration in the pharmaceutical industry. (2006). Becker, Markus C. ; Lillemark, Morten.
    In: Research Policy.
    RePEc:eee:respol:v:35:y:2006:i:1:p:105-120.

    Full description at Econpapers || Download paper

  38. EQUITY OF ACCESS TO INNOVATIVE MEDICINES: MISSION IMPOSSIBLE?. (2006). Attridge, Jim.
    In: Economic Affairs.
    RePEc:bla:ecaffa:v:26:y:2006:i:3:p:17-23.

    Full description at Econpapers || Download paper

  39. New-product success in the pharmaceutical industry: how many bites at the cherry?. (2005). Demeire, Edouard ; Corstjens, Marcel ; Horowitz, Ira.
    In: Economics of Innovation and New Technology.
    RePEc:taf:ecinnt:v:14:y:2005:i:4:p:319-331.

    Full description at Econpapers || Download paper

  40. The disaggregated technology production function: A new model of university and corporate research. (2005). Tassey, Gregory.
    In: Research Policy.
    RePEc:eee:respol:v:34:y:2005:i:3:p:287-303.

    Full description at Econpapers || Download paper

  41. Sources of productivity growth in the Spanish pharmaceutical industry (1994-2000). (2004). González Fidalgo, Eduardo ; Gonzalez, Eduardo ; Gascon, Fernando .
    In: Research Policy.
    RePEc:eee:respol:v:33:y:2004:i:5:p:735-745.

    Full description at Econpapers || Download paper

  42. Technology Push, Demand Pull And The Shaping Of Technological Paradigms - Patterns In The Development Of Computing Technology. (2002). Dolfsma, Wilfred ; van den Ende, J. C. M., .
    In: ERIM Report Series Research in Management.
    RePEc:ems:eureri:239.

    Full description at Econpapers || Download paper

  43. Analysis of Dynamic Characteristics of the Economic Systems in the Region of the CIS. (). Pshenichnikova, Svetlana Nikolaevna ; Plotnikov, Vladimir Aleksandrovich.
    In: Administrative Consulting.
    RePEc:acf:journl:y::id:145.

    Full description at Econpapers || Download paper

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2024-12-15 16:49:22 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated October, 6 2023. Contact: CitEc Team.